WELCOME TO The PHARMACEUTICAL REPORT
Genetics & Applications
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Biospace.com | March 28, 2019
Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial. The trial is evaluating enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who had previously received both platinum-based chemotherapy and a checkpoint inhibitor. Enfortumab vedotin is an antibody-drug conjugate (ADC) targeting Nectin-4. Nectin-4 is highly expressed in urothelial cancers, as well as other solid tumors. The drug re...
FiercePharma | February 07, 2020
It wasn’t long ago when Seattle Genetics shareholders moved past earlier letdowns and cheered strong performance from key cancer drug Adcetris. But now, they might be disappointed again. During the fourth quarter, Adcetris pulled in sales of $166.2 million in the U.S. and Canada, a 26% increase over 2018. Still, the number came below the Street’s expectations of $174.5 million as well as its own third-quarter sales of $167.6 million. The fourth-quarter haul brought the antibody-drug ...
Medgadget | January 08, 2019
Researchers at the University of Arizona have developed an advanced optogenetics device that can stimulate multiple areas of the brain at once and control the intensity of emitted light. The miniaturized device is wireless and battery-free, and the researchers hope that it will pave the way to treating severe neurological disorders and controlling chronic pain. Optogenetics involves loading specific neurons with proteins called opsins, which can stimulate a neuron to fire when exposed to light. ...
Pharmacy Business | January 14, 2020
The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE